Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

Lost Money on Incyte Corporation(INCY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study

Incyte (INCY) led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.

Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study

The biopharmaceutical company provided disappointing updates on two research studies.

Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock.

On Monday, Incyte Corporation INCY announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).

Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges

Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another. The post Incyte Collapses.

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs.

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery,.

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alcoa

GE Vernova LLC

RadNet

Semtech

TG Therapeutics

Vertex Pharmaceuticals

None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.

BioMarin Pharmaceutical

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is the best option for those looking for undervalued stocks?

BMRN vs. INCY: Which Stock Is the Better Value Option?

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. New product approvals, like Niktimvo, should diversify Incyte's revenue and reduce reliance on Jakafi. The EPS miss is mostly related to elevated R&D spending, which will be critical to ease investors' fears about a potential loss of revenue from Jakafi in the coming years.

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

On Tuesday, Incyte Corporation  INCY reported third-quarter revenue of $1.14 billion, up 24% year over year, beating the consensus of $1.08 billion.

Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024 at 2:00 pm (EST) Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 am (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global.

Incyte to Present at Upcoming Investor Conferences

Incyte stock broke out Tuesday after sales of the company's two key products beat analysts' third-quarter projections.

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges

Incyte Corporation (NASDAQ:INCY ) Q3 2024 Results Conference Call October 29, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Steven Stein - Chief Medical Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Barry Flannelly - General Manager, North America Conference Call Participants Michael Schmidt - Guggenheim Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Matt Phipps - William Blair James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Derek Archila - Wells Fargo David Lebowitz - Citibank Marc Frahm - TD Cowen Brian Abrahams - RBC Capital Markets Andy Chen - Wolfe Research Jay Olson - Oppenheimer Gavin Clark-Gartner - Evercore ISI Evan Seigerman - BMO Capital Markets Tazeen Ahmad - Bank of America Srikripa Devarakonda - ­Truist Securities Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Incyte Third Quarter Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript

On Tuesday, Incyte Corporation  INCY reported third-quarter revenue of $1.14 billion, up 24% year over year and beating the consensus of $1.08 billion.

Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura

Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.

INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings

Incyte beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong.

Incyte raises 2024 sales forecast for top-selling drug Jakafi

Incyte (INCY) came out with quarterly earnings of $1.07 per share, missing the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.10 per share a year ago.

Incyte (INCY) Q3 Earnings Miss Estimates

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs.

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SCTopEmployers--Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List.

Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List

INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.

Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program.

News for Incyte Stock (INCY)